Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Go back to Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate| Merck & Co. (NYSE: MRK) | Delayed: 128.55 +0.22 (0.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.33 | 52 Week High | $65.46 | |||
| Open | $130.96 | 52 Week Low | $47.97 | |||
| Day High | $131.08 | P/E | 87.45 | |||
| Day Low | $128.34 | EPS | $1.47 | |||
| Volume | 1,156,435 | |||||
